Biopharmaceutical - Clinical-stage development focusing on neurological disorders and brain-targeted therapeutics
Strategic Profile
Oragenics is striving to revolutionize neurological care through proprietary intranasal delivery technology that has the potential to enable targeted, non-invasive therapeutics for brain-related conditions. The company closed a $16.5 million Series H convertible preferred stock offering on July 2, 2025, which restored equity and provides runway to advance lead candidate ONP-002 through Phase IIa in Australia and to prepare for potential U.S. Phase IIb trials.
Cyborg Score Rationale
Oragenics regained full NYSE American compliance effective October 20, 2025 after restoring stockholders' equity above the required $6 million threshold. While the company has secured funding and advanced its lead program, it remains development-stage with execution risk tied to Phase 2a trial outcomes.
Top Insights
Phase IIa concussion trial initiation expected in Q4 2025 for ONP-002.
Strategic collaboration with Receptor.AI to apply AI-driven receptor profiling to Oragenics' molecules acquired in 2023, aiming to accelerate preclinical candidate identification for neurological and psychiatric indications including Alzheimer's, Parkinson's, PTSD, opioid addiction, and anxiety.
Company successfully restored regulatory compliance after capital raise addressing stockholders' equity threshold.
Platform potentially addresses large unmet need in brain-targeted therapeutics via intranasal delivery.
Named Competitors
Brain-targeted therapeutics — Companies pursuing treatments for neurological disorders and concussion
Recent Developments
(February 2026) Participating in SCOPE Summit 2026 to engage clinical operations leaders ahead of Phase 2a trial
(January 2026) Presenting at Sequire Investor Summit 2026 covering ONP-002 clinical program
(October 2025) Regained full NYSE American compliance after restoring stockholders' equity
(July 2025) Closed $16.5 million Series H convertible preferred stock offering
Open the full interactive Oragenics, Inc. report
Strategic research, analyst-debate audio, full Cyborg Score breakdown across 11 dimensions, and saved-company audio playlists.